Besponsa
NDC 0008-0100 · Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Generic nameinotuzumab ozogamicin
Dosage formINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
RouteINTRAVENOUS
Active ingredient(s)INOTUZUMAB OZOGAMICIN
Strength.25 mg/mL
Pharmacologic classCD22-directed Antibody Interactions [MoA], CD22-directed Immunoconjugate [EPC], Decreased DNA Integrity [PE], Immunoconjugates [CS], Increased Cellular Death [PE]
Marketing categoryBLA
Packages
0008-0100-01 — 1 VIAL, SINGLE-DOSE in 1 CARTON (0008-0100-01) / 4 mL in 1 VIAL, SINGLE-DOSE
Billed under HCPCS
J9229 — Injection, inotuzumab ozogamicin, 0.1 mg Medicare Part B payment limit (ASP + 6%): $2873.10